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Statin Therapy Before Transition to End-Stage Renal Disease With
Posttransition Outcomes
Melissa Soohoo, MPH; Hamid Moradi, MD; Yoshitsugu Obi, MD, PhD; Connie M. Rhee, MD, MSc; Elvira O. Gosmanova, MD;
Miklos Z. Molnar, MD, PhD; Moti L. Kashyap, MD, MSc; Daniel L. Gillen, PhD; Csaba P. Kovesdy, MD;
Kamyar Kalantar-Zadeh, MD, MPH, PhD; Elani Streja, MPH, PhD
Background-—Although studies have shown that statin therapy in patients with non–dialysis-dependent chronic kidney disease
was associated with a lower risk of death, this was not observed in dialysis patients newly initiated on statins. It is unclear if statin
therapy beneﬁts administered during the predialysis period persist after transitioning to end-stage renal disease.
Methods and Results-—In 47 720 veterans who transitioned to end-stage renal disease during 2007 to 2014, we examined the
association of statin therapy use 1 year before transition with posttransition all-cause and cardiovascular mortality and
hospitalization incidence rates over the ﬁrst 12 months of follow-up. Associations were examined using multivariable adjusted Cox
proportional hazard models and negative binomial regressions. Sensitivity analyses included propensity score and subgroup
analyses. The cohort’s meanSD age was 7111 years, and the cohort included 4% women, 23% blacks, and 66% diabetics. Over
12 months of follow-up, there were 13 411 deaths, with an incidence rate of 35.3 (95% CI, 34.7–35.8) deaths per 100 person-
years. In adjusted models, statin therapy compared with no statin therapy was associated with lower risks of 12-month all-cause
(hazard ratio [95% CI], 0.79 [0.76–0.82]) and cardiovascular (hazard ratio [95% CI], 0.83 [0.78–0.88]) mortality, as well as with a
lower rate of hospitalizations (incidence rate ratio [95% CI], 0.89 [0.87–0.92]) after initiating dialysis. These lower outcome risks
persisted across strata of clinical characteristics, and in propensity score analyses.
Conclusions-—Among veterans with non–dialysis-dependent chronic kidney disease, treatment with statin therapy within the
1 year before transitioning to end-stage renal disease is associated with favorable early end-stage renal disease outcomes. ( J Am
Heart Assoc. 2019;8:e011869. DOI: 10.1161/JAHA.118.011869.)
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D yslipidemia is an established risk factor for cardiovas-cular events and mortality in the general population,1
and cholesterol-lowering drugs, especially statins, have been
shown to improve outcomes among such patients at risk of
cardiovascular events. Chronic kidney disease (CKD) is a
progressive and irreversible condition associated with a high
risk of cardiovascular morbidity and mortality,2 and current
guidelines recommend treatment with statins irrespective of
cholesterol levels and kidney function among adult patients
with non–dialysis-dependent (NDD) CKD.1,3,4 The beneﬁts of
statin therapy in patients with NDD-CKD were observed in the
subgroup analysis of the SHARP (Study of Heart and Renal
Protection) trial,5 in which the statin combined therapy (ie,
simvastatin plus ezetimibe), compared with placebo, reduced
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the risk of major atherosclerotic events by 22% among 6247
patients with NDD-CKD. The SHARP trial also included 3023
maintenance dialysis patients, but the cardiovascular beneﬁt
of the statin combined therapy was not clearly observed in
this dialysis patient subgroup. Given these observations, along
with the results from the other clinical trials,5–7 the current
guidelines do not recommend initiating statin therapy in
patients already receiving maintenance dialysis.1,3,4
In the SHARP trial, however, patients with NDD-CKD who
transitioned to dialysis during the follow-up period were
analyzed as part of the NDD-CKD group rather than
separately. Therefore, it remains unclear whether the beneﬁts
of statin therapy observed in the NDD-CKD group persisted
after transition to end-stage renal disease (ESRD) (ie, beneﬁts
of pre-ESRD statin use on post-ESRD outcomes). Thus, in a
large cohort of US veteran patients transitioning to ESRD, we
examined the associations of statin therapy in the year before
transition with posttransition 12-month mortality risk and
hospitalization rate.
Methods
Study Population and Data Source
We retrospectively examined data from the Transition of Care
in Chronic Kidney Disease US Renal Data System (USRDS)
Special Study Center, which is focused on investigating the
transition to renal replacement therapy among patients with
incident ESRD.2,8,9 The USRDS identiﬁed the source cohort of
85 505 veterans who transitioned to renal replacement
therapy from October 1, 2007, to March 30, 2014. We
excluded 1958 patients for missing censor information;
25 792 patients for missing prescription medication informa-
tion in the 1 year before ESRD transition; and 10 035
patients for receiving less than half of a year of statin
prescription. The ﬁnal cohort was composed of 47 720
veterans with incident ESRD, of whom 22 151 were not
prescribed pre-ESRD statin therapy and 25 569 were pre-
scribed pre-ESRD statin therapy (Figure S1).
This study was approved by the Tibor Rubin and Memphis
Veterans Affairs Medical Centers’ Institutional Review Boards.
The written consent requirement was waived given the large
sample size, patient anonymity, and nonintrusive nature of this
study. The data and study materials cannot be made available
to other researchers for purposes of reproducing the results or
replicating the procedure given that data are provided under
contract with the US Department of Veterans Affairs (VA) and
are at its disposal. Hence, this center may not override the
contractual agreements. Additional details about the analytical
methods can be provided on request.
Demographics and Clinical Measurements
Baseline characteristics were developed from the combination
of 3 national databases: USRDS, VA, and Centers for
Medicare and Medicaid Services (CMS). Data on marital and
smoking status10 were obtained from VA records only. Initial
dialysis characteristics, including modality and access type,
were obtained from USRDS ﬁles only. Preexisting comorbidity
information at the time of transition was extracted from VA
and CMS databases using International Classiﬁcation of
Diseases, Ninth Revision (ICD-9), Diagnostic and Procedural
codes and Current Procedural Terminology codes as guided
by those listed in the Deyo Charlson Comorbidity Index and
CMS Chronic Conditions. The presence of comorbidities was
determined using a 1 inpatient or 2 outpatient visit algorithm.
The Charlson Comorbidity Index was calculated without renal
disease. The presence of cardiovascular disease (CVD) was
determined as the presence of any prior atrial ﬁbrillation,
ischemic heart disease, myocardial infarction (MI), congestive
heart failure (CHF), peripheral vascular disease, or cere-
brovascular disease.
Data on most pre-ESRD (prelude) laboratory measure-
ments were sourced from VA databases. Serum creatinine
data and, thus, estimated glomerular ﬁltration rate within the
past 90 days before transition were obtained from the VA
Corporate Data Warehouse LabChem ﬁle and the USRDS CMS
2728 Medical Evidence form. Other serum laboratory mea-
surements, including lipid panel, were obtained from the VA
Clinical Perspective
What Is New?
• Although the SHARP (Study of Heart and Renal Protection),
AURORA (A Study to Evaluate the Use of Rosuvastatin in
Subjects on Regular Hemodialysis: An Assessment of
Survival and Cardiovascular Events), and 4D (Deutsche
Diabetes Dialyse Studie) clinical trials showed the relation-
ship of statin therapy with cardiovascular outcomes across
different stages of chronic kidney disease, the association
of statin use in late-stage chronic kidney disease with post–
end-stage renal disease transition outcomes has not
previously been demonstrated.
• Herein, we demonstrate, among a cohort of US veterans
transitioning to end-stage renal disease, the beneﬁt of statin
therapy before transition with posttransition mortality and
hospitalization outcomes.
What Are the Clinical Implications?
• This analysis supports current guidelines, which indicate
treatment of statin therapy for patients with late-stage
kidney disease and potentially transitioning to end-stage
renal disease.
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Decision Support System National Data Extracts Laboratory
Results ﬁle, whereas body mass index and blood pressures
were obtained from the VA Corporate Data Warehouse Vital
Signs ﬁle. With the exception of estimated glomerular
ﬁltration rate, for which a single measurement was used,
laboratory measurements within the baseline 1 year prelude
period were averaged.
Exposure Measurement
Both inpatient and outpatient medication data were sourced
from CMS Medicare Part D and VA pharmacy dispensation
records.11 Lipid-lowering drugs, including statins, were
extracted using speciﬁc VA drug class codes and names.
Patients covered with prescriptions for at least half of the
1 year before transition to ESRD were characterized as
receiving statin therapy. Patients with medication prescrip-
tions for other treatments in the 1 year prelude period, yet
not prescribed statin therapy during the same time period,
were categorized as not receiving statin therapy. Patients
covered with prescriptions for statin therapy for less than half
of the year were excluded from our main analyses.
Outcome Assessment
The primary outcomes were all-cause and cardiovascular
mortality in the ﬁrst 12 months after transition to ESRD. The
secondary outcome was hospitalization incidence in the ﬁrst
12 months after transition to ESRD.
All data on all outcomes and censoring events were
obtained from USRDS, VA, and CMS data sets. Follow-up
started at ESRD initiation until death, kidney transplantation,
lost to follow-up, end of the 12-month follow-up period, or date
of administrative censoring, whichever occurred ﬁrst. The last
date of follow-up was September 2, 2014, or June 30, 2014, for
all-cause events or cardiovascular mortality, respectively.
Cardiovascular causes of death, including MI, cardiac
arrest, CHF, valvular heart disease, cardiac arrhythmia,
cardiomyopathy, pericarditis, cerebrovascular event, pul-
monary embolus, and atherosclerotic heart disease, were
obtained from USRDS records only.
Cardiovascular mortality was examined in a subset of
patients with an available and known cause of death from
USRDS ﬁles. The subset cohort included 42 771 and 37 729
patients for 12-month and 7-year cardiovascular mortality,
respectively.
Statistical Analysis
Baseline patient characteristics were presented as meanSD
or median (25th–75th percentile) for continuous variables
and proportions for categorical variables, as appropriate.
Standardized differences were used to compare characteris-
tics between statin therapy groups.12
For all analyses, nonreceipt of statin therapy served as the
referent group. Cox proportional hazard models were used to
examine the association of statin therapy with 12-month
posttransition all-cause mortality and cardiovascular mortal-
ity. Moreover, we examined the association of statin therapy
with 12-month posttransition hospitalization incidence rate
using a negative binomial regression model.
All associations were examined in unadjusted and adjusted
models, which included adjustment for demographics (age,
sex, race, and ethnicity) and the following comorbidities:
Charlson Comorbidity Index, diabetes mellitus, atheroscle-
rotic CVD (deﬁned as the presence of MI, peripheral vascular
disease, or ischemic heart disease), atrial ﬁbrillation, CHF,
and cerebrovascular disease. Moreover, we performed sep-
arate adjustments for indicators of pre-ESRD care, including
initial access type and VA or CMS nephrology outpatient
visits in the year before ESRD transition (use of nephrology
services). Furthermore, we examined associations of statin
therapy with all outcomes across a priori selected subgroups.
Formal tests of interactions were performed using Wald’s test
under the adjusted model. Among all patients with any statin
therapy in the pre-ESRD period (n=35 604), we modeled
statin therapy exposure as the total number of days in
association with mortality outcomes using restricted cubic
splines with best placed knots at the 5th, 35th, 65th, and
95th percentiles of exposure.
In sensitivity analyses, we also examined associations in
patients with available and complete laboratory information
in the past 1 year before transition. Models were additionally
adjusted for smoking status, last estimated glomerular
ﬁltration rate before transition, and the following averaged
laboratory variables: body mass index, serum hemoglobin,
albumin, calcium, white blood cell count, bicarbonate, and
blood urea nitrogen. We also examined associations for all
outcomes for up to 7 years of follow-up. Finally, we
calculated propensity scores (PS) for bias reduction as well
as to account for patient differences between groups. The
PS was calculated as the probability of statin therapy given
by the covariates from our adjusted model. We then used
the PS for our mortality analyses, including PS matching
(n=19 364 patients in each arm), PS adjustment in the
overall cohort, and PS stratiﬁcation in the overall cohort
using a doubly robust estimation approach.13
The proportionality assumption was checked using plots of
log (log[survival rate]) against log(survival time). Data on
demographic and comorbid conditions used in analyses were
missing for <0.40% of the cohort and imputed using means or
missing categories. All analyses were conducted using SAS
Enterprise Guide (7.1) (Cary, NC) and Stata 15 (College
Station, TX).
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Results
The study cohort comprised 47 720 patients, and their
meanSD age was 7111 years (Table 1). The cohort also
included 4% women, 23% blacks, 66% diabetics, and 78%
patients with CVD. Overall, 54% of the cohort was prescribed
statin therapy before ESRD initiation. Patients were pre-
scribed statin therapy for an average of 27745 (median
[25th–75th percentile], 278 [247–314]) days in the year
before transition to ESRD. Patients receiving statin therapy
were more likely to have diabetes mellitus; have CVD history,
including ischemic heart disease, MI, CHF, peripheral vascular
disease, and cerebrovascular disease; use an arteriovenous
ﬁstula during initial dialysis treatment; and have greater use of
VA nephrology services in the year before transition. They
were also less likely to be black and had a lower prevalence of
liver disease.
Association of Statin Therapy With All-Cause and
Cardiovascular Mortality
Over 12 months of follow-up, there were 13 411 all-cause
deaths, with an incidence rate (95% CI) of 35.3 (34.7–35.8)
deaths per 100 person-years. Patients who received statin
therapy in the year before transition had a lower crude all-cause
mortality rate over the 12-month follow-up period compared
with those who did not receive statin therapy (33.1 [95% CI,
32.3–33.8] versus 37.9 [95% CI, 37.0–38.8] per 100 person-
years, respectively). In survival analyses, patients who received
statin therapy had a 12% lower all-cause mortality risk in the
unadjustedmodel (hazard ratio (HR), 0.88 [95% CI, 0.85–0.91]),
which was slightly strengthened after adjustment for demo-
graphics and comorbidities (HR [95% CI], 0.79 [0.76–0.82])
(Table 2). Moreover, there were no differences observed in the
comparison of crude cardiovascular mortality rates and in the
unadjusted Cox model. However, in adjusted models, patients
receiving statin therapy had a 17% lower risk of cardiovascular
death (HR [95% CI], 0.83 [0.78–0.88]) (Table 2).
Association of Statin Therapy With
Hospitalization Rate
Over the ﬁrst 12 months post-ESRD transition, patients who
received statin therapy in the 1 year before ESRD transition
had a lower overall rate of hospitalizations compared with
patients who did not receive statin therapy (rate [95% CI],
206.8 [204.8–208.8] versus 209.5 [207.4–211.7] hospital-
izations per 100 patient-years, respectively). Patients receiv-
ing statin therapy had a lower hospitalization rate, persisting
in all models (adjusted incidence rate ratio [95% CI]), 0.89
[0.87–0.92]) (Table 2).
Subgroup Analyses
Across all strata, receipt of statin therapy compared with no
receipt of statin therapy was associated with a lower risk of all
outcomes (Figure, Table S1). For both all-cause and cardio-
vascular mortality, lower HRs with statin therapy were
observed for younger patients (P-interaction<0.0001 for
all-cause mortality; P-interaction=0.03 for cardiovascular
mortality) and nondiabetic patients (P-interaction=0.02 for
all-cause mortality; P-interaction=0.011 for cardiovascular
mortality). A similar effect of younger age was observed for
hospitalization incidence rate (P-interaction=0.0003). More-
over, effect modiﬁcation by black race was observed for
mortality outcomes, whereby black patients compared with
non-black patients had a lower death HR for statin therapy
versus no statin therapy. There was also effect modiﬁcation
by CVD, for which a lower death HR and a lower incidence
rate ratio were observed in patients without CVD for those
who received statin therapy. Subgroup analyses by decom-
posed CVD are presented in Figure S2 and showed similar
results; within all subgroups, patients who received statin
therapy had a lower estimate of event, compared with that of
those who did not receive statin therapy. However, with the
exception of atrial ﬁbrillation, for both outcomes of all-cause
mortality and hospitalization rate, we observed effect modi-
ﬁcation by all individual CVDs where a lower risk was
observed for patients without the CVD comorbidity. Effect
modiﬁcation was present for CHF, peripheral vascular disease,
and atherosclerotic CVD for the cardiovascular mortality
outcome only. Presence of liver disease also impacted the all-
cause mortality risk and hospitalization incidence rates,
whereby the HR and incidence rate ratio, respectively, for
patients who received statin therapy were lower in those with
versus without liver disease. Smoking and 1-year averaged
prelude low-density lipoprotein level did not modify the
association of statin therapy with outcomes.
Sensitivity Analyses
Associations of statin therapy with a longer follow-up for 7-year
outcomes were similar to ﬁndings in the main analyses
(Figure S3), including hospitalization incidence rate ratio (0.90
[95% CI, 0.88–0.92]). Similar associations were observed after
additional adjustment for pre-ESRD care indexes, including
initial vascular access type and nephrology use for both all-
cause and cardiovascular mortality outcomes, as well as
hospitalization rate (Table S2). When modeled as a continuous
variable, the number of days of statin therapy exposure showed
a graded and inverse association with mortality outcomes
(reference, 182 days), among a larger cohort of patients with
any receipt of statin therapy in the pre-ESRD period. A longer
amount of time receiving pre-ESRD statin therapy (more than
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Table 1. Baseline Characteristics of 47 720 Patients Stratiﬁed by Use of Statin Therapy Before ESRD Transition
Characteristics
Total Statin Therapy No Statin Therapy
Standardized Difference(N=47 720) (n=25 569, 53.6%) (n=22 151, 46.4%)
Cardiovascular disease, %
No 22 14 30 0.38
Yes 78 86 70 0.09
Atrial fibrillation 17 18 15 0.07
ISHD 59 68 48 0.41
MI 26 31 20 0.26
CHF 55 61 49 0.24
PVD 38 44 32 0.25
Cerebrovascular disease 31 36 26 0.23
Age, y 7111 7210 7112 0.14
Aged <65 y, % 29 25 33 0.16
Aged 65–<75 y, % 27 29 25 0.09
Aged ≥75 y, % 44 46 43 0.07
Female sex, % 4 3 5 0.09
Race, %
White 73 76 69 0.16
Black 23 20 27 0.16
Other 4 4 5 0.01
Hispanic ethnicity, % 6 6 6 0.01
Married status, % 60 62 58 0.08
CCI 4 (2–6) 4 (3–6) 3 (2–5) 0.24
Comorbidities, %
Diabetes mellitus 66 74 57 0.37
Anemia 72 74 69 0.12
Depression 22 23 22 0.04
Hyperlipidemia 78 91 63 0.71
COPD 42 45 39 0.12
Peptic ulcer disease 7 7 7 0.02
Liver disease 11 8 15 0.22
Cancer 24 24 25 0.02
Smoking status, %
Never 30 30 30 0.11
Current 35 33 37
Past 35 37 32
eGFR at initiation, mL/min per 1.73 m2 10.1 (7.3–13.8) 10.3 (7.6–13.9) 9.8 (7.0–13.6) 0.00
1 year Averaged lipids, mg/dL
HDL 4014 3913 4115 0.10
LDL 8535 8032 9438 0.40
Cholesterol 15546 14942 16550 0.35
Triglycerides 124 (87–181) 127 (89–182) 120 (84–181) 0.01
Continued
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half a year) was associated with a lower risk of all-cause and
cardiovascular mortality (Figure S4A and S4B).
Furthermore, although data on laboratory measurements
were limited, serum levels of albumin, white blood cell count,
blood urea nitrogen, and hemoglobinwere comparable between
the statin therapy and no statin therapy groups (Table S3).
However, for patients receiving statin therapy, bodymass index
and serum bicarbonate and calcium levels were higher,
compared with patients receiving no statin therapy. Nonethe-
less, associationswere similar and only slightly attenuated after
additional adjustment for these markers (Table S4) in analysis
restricted to patients with complete laboratory and smoking
information. Patients included in this sensitivity analysis had
similar characteristics to those excluded, with the exception
that they had a greater use of nephrology services, in particular
within the VA, and hence also had more of these VA-drawn
laboratory measurements available (Table S5).
Finally, we observed similar associations between statin
therapy compared to no statin therapy and mortality
outcomes across a series of PS analyses. In matched
analyses, both statin therapy and no statin therapy groups
were similar in baseline patient characteristics (Table S6).
After adjustment, statin therapy was associated with a 20%
lower risk of both all-cause and cardiovascular mortality
compared with no statin therapy, in matched analyses
(Table S7). Moreover, this relationship of statin therapy and
lower risk of all-cause and cardiovascular mortality was
similar in PS adjustment models and stratiﬁcation by PS
tertiles.
Discussion
In a contemporary cohort of 47 720 veterans with incident
ESRD, patients prescribed statin therapy for at least half of
the year before ESRD transition had a lower risk of both all-
cause and cardiovascular mortality and a lower hospitalization
incidence rate in the ﬁrst 12 months after ESRD initiation.
This relationship was consistent across strata of clinical
Table 1. Continued
Characteristics
Total Statin Therapy No Statin Therapy
Standardized Difference(N=47 720) (n=25 569, 53.6%) (n=22 151, 46.4%)
Initial dialysis modality, %
Hemodialysis 82 83 81 0.06
Peritoneal dialysis 5 5 5
Other/unknown 12 12 13
Initial access type, %
Arteriovenous fistula/arteriovenous graft 21 23 19 0.10
CVC 70 68 72
Other 9 9 10
Pre-ESRD nephrology visits
Any VA or CMS physician nephrology
visits in the year before transition, %
69 72 66 0.14
No. of VA or CMS physician nephrology
visits in the year before transition
3 (0–8) 4 (0–8) 3 (0–7) 0.07
Any VA nephrology visits in the
year before transition, %
33 39 28 0.24
No. of VA nephrology visits in the
year before transition
0 (0–2) 0 (0–3) 0 (0–1) 0.23
Any CMS physician nephrology visits
in the year before transition, %
43 42 44 0.05
No. of CMS physician nephrology visits
in the year before transition
0 (0–5) 0 (0–5) 0 (0–5) 0.04
Data are presented as proportion, meanSD, or median (25th–75th percentile), where appropriate, and compared between groups using standardized differences. Standardized
differences of ≥0.2 are considered as a meaningful imbalance, where 0.8, 0.5, and 0.2 represent large, medium, and small imbalances, respectively. CCI indicates Charlson Comorbidity
Index; CHF, congestive heart failure; CMS, Centers for Medicare and Medicaid Services; COPD, chronic obstructive pulmonary disease; CVC, central venous catheter; eGFR, estimated
glomerular ﬁltration rate; ESRD, end-stage renal disease; HDL, high-density lipoprotein; ISHD, ischemic heart disease; MI, myocardial infarction; LDL, low-density lipoprotein; PVD,
peripheral vascular disease; VA, Veterans Affairs.
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characteristics, during longer periods of follow-up, after
further adjustment for laboratory measures, pre-ESRD care
indexes, and PS analyses.
Associations of pre-ESRD statin therapy compared with no
statin therapy with clinical outcomes in the ﬁrst year after
transition to ESRD exhibited heterogeneous protective effects
across a priori selected subgroups. There was a progressive
decline in favorable outcomes observed with statin therapy
with advancing age, particularly among patients aged
≥75 years. This is supported by previous randomized trials
that reported similar data.14 Furthermore, a meta-regression
of randomized controlled statin trials showed that statins may
have a decreased to null effect on all-cause mortality and
cardiovascular events in populations with higher noncardio-
vascular mortality risk.15 Older patients receiving dialysis
have a marked excess of noncardiovascular mortality risk.16
Appropriate lipid management in elderly patients, including
those transitioning to dialysis, is a complex issue that merits
further investigation.17
Paradoxically, despite the fact that in the general
population, diabetes mellitus and CVD are strong risk
factors indicating a recommendation for statin treatment,
in this cohort of patients transitioning to ESRD, the statin
beneﬁt was stronger in patients without these comorbidities.
This observation is consistent with a meta-analysis of
randomized clinical trials showing a trend toward diminished
beneﬁt of statins in patients with diabetes mellitus com-
pared with those without diabetes mellitus in terms of
coronary death.18 One potential explanation for these
ﬁndings may be that patients with advanced CKD and
preexisting CVD or diabetes mellitus have more advanced
vascular disease, which renders statin therapy to be less
effective in altering outcomes. Diabetes mellitus and CVD
have both been associated with reduced endothelial func-
tion, and statin-mediated vascular responsiveness may be
lower in more advanced disease.19–23 In addition, statins are
involved in stabilizing plaques with soft lipid cores.24
Patients with diabetes mellitus and CVD comorbidity may
have more ﬁbrous plaques and medial calciﬁcation that are
less vulnerable and may beneﬁt less from statin-induced
plaque stabilization.25,26 However, future studies will need to
evaluate these ﬁndings in more detail. Our data also show a
stronger impact of statin therapy on outcomes in blacks
compared with nonblacks. Previous studies have shown
similar results in hypertensive patients27 and in transplant
patients.28 Moreover, our group has also shown that blacks
have better nutritional status at the transition to dialysis
and, consequently, better survival.29 We have also shown
that black US veterans were found to have better survival
across stages of kidney disease.30–32 One potential expla-
nation was related to the fact that black patients have less
calciﬁed atherosclerotic lesions, potentially allowing them to
be more responsive to statin therapy.33–35 Additional studies
will be needed to establish whether the survival advantage of
statin therapy in blacks is related to a racial difference in
response to this treatment versus better overall nutritional
Table 2. Association of Pre-ESRD Statin Therapy (vs No Statin Therapy) With Posttransition 12-Month Mortality and
Hospitalizations
Variable No. of Patients
Unadjusted Adjusted
No. of Events
Rate per 100
Person-Years (95% CI) P Value Ratio (95% CI) P Value Ratio (95% CI)
All-cause mortality
Total 47 720 13 411 35.3 (34.7–35.8) <0.0001 0.88 (0.85–0.91) <0.0001 0.79 (0.76–0.82)
No 22 151 6541 37.9 (37.0–38.8)
Yes 25 569 6870 33.1 (32.3–33.8)
Cardiovascular mortality
Total 42 771 4373 12.3 (11.9–12.7) 0.7069 0.99 (0.93–1.05) <0.0001 0.83 (0.78–0.88)
No 19 696 1994 12.4 (11.9–12.9)
Yes 23 075 2379 12.2 (11.7–12.7)
Hospitalization incidence
Total 47 720 79 144 208.0 (206.6–209.5) 0.077 0.98 (0.95–1.00) <0.0001 0.89 (0.87–0.92)
No 22 151 36 167 209.5 (207.4–211.7)
Yes 25 569 42 977 206.8 (204.8–208.8)
Adjusted covariates included age, sex, race, and ethnicity as well as the following comorbidities: Charlson Comorbidity Index, diabetes mellitus, atherosclerotic cardiovascular disease
(deﬁned as the presence of myocardial infarction, peripheral vascular disease, or ischemic heart disease), atrial ﬁbrillation, congestive heart failure, and cerebrovascular disease. Hazard
ratios (HR) and incidence rate ratios (IRR) are presented for mortality and hospitalization outcomes, respectively. ESRD indicates end-stage renal disease.
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Hazard Ratio for 12-month Cardiovascular Mortality
10.6 0.8
Hazard Ratio for 12-month All-Cause Mortality
10.6 0.8
All
Age <65 years
Age 65-<75 years
Age ≥75 years
Non-Black
Black
No Diabetes Mellitus
Diabetes Mellitus
No CVD
CVD
No Liver Disease
Liver Disease
Never Smoker
Current Smoker
Past Smoker
LDL<70 mg/dL
LDL >70 mg/dL
P-Int
<0.001
0.02
0.02
0.002
<0.001
0.06
0.82
P-Int
0.03
0.01
0.011
0.05
0.23
0.10
0.62
Incidence Rate Ratio for 12-month Hospitalizations
10.8 0.9
All
Age <65 years
Age 65-<75 years
Age ≥75 years
Non-Black
Black
No Diabetes Mellitus
Diabetes Mellitus
No CVD
CVD
No Liver Disease
Liver Disease
Never Smoker
Current Smoker
Past Smoker
LDL<70 mg/dL
LDL >70 mg/dL
P-Int
<0.001
0.25
0.05
0.002
<0.001
0.91
0.64
Figure. Associations of pre–end-stage renal disease statin therapy vs no statin therapy with 12-month all-cause mortality,
cardiovascular mortality, and hospitalization incidence rate in a priori selected subgroups. Adjusted covariates included age, sex, race,
and ethnicity as well as the following comorbidities: Charlson Comorbidity Index, diabetes mellitus, atherosclerotic cardiovascular
disease (CVD; deﬁned as the presence of myocardial infarction, peripheral vascular disease, or ischemic heart disease), atrial
ﬁbrillation, congestive heart failure, and cerebrovascular disease. LDL, low-density lipoprotein; P-Int, p-value for interaction.
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status given that malnourished patients are less responsive
to statin therapy.17
Patients with liver disease in our cohort had a greater
beneﬁt from statin therapy. This is supported by clinical trials
in the general population reporting comparable ﬁndings.36,37
Older guidelines state that chronic liver disease is an absolute
contraindication for statin therapy.38 However, a recent
analysis found statins to be effective and safe in patients
with chronic liver disease.39 Our ﬁndings suggest that pre-
ESRD statin therapy may be beneﬁcial among patients with
liver disease and transitioning to ESRD.
Last, we have also found that the results of our associ-
ations are similar whether the patients achieved a target
low-density lipoprotein cholesterol level of 70 mg/dL or
not. These ﬁndings support the “ﬁre and forget” strategy of
some of the guidelines, in which patients at high risk for
cardiovascular outcomes are prescribed statins without
further testing or dose adjustment for achievement of lipid-
lowering goals.3,40
In our cohort, patients who received statins also had a
lower incidence rate of hospitalization in the 12 months after
transition. Data on veterans transitioning to ESRD showed
that the top 2 causes of hospitalization after transition for
dialysis patients are septicemia and complications of arteri-
ovenous grafts.2 Previous studies have also shown that
treatment with statins was associated with a lower risk of
both arteriovenous graft failure41 and hospitalization for
sepsis in dialysis patients.42 The former has also been
observed in post hoc analyses of SHARP trial patients, but
when combined with another clinical trial, this was not shown
to be statistically signiﬁcant.43 Hospitalizations for cardiovas-
cular events and revascularization in dialysis patients may be
comparatively overshadowed by the frequency of hospitaliza-
tions attributable to septicemia or graft complications,
particularly in the ﬁrst months after transition. In our cohort,
equally for patients receiving statin therapy and not receiving
statin therapy, septicemia was the second most frequently
listed primary cause of hospitalization admission in the ﬁrst
12 months post-ESRD transition (Table S8). Although a post
hoc analysis of the SHARP trial showed no difference in
adverse events between study arms, there was no analysis that
examined differences in septicemia in dialysis patients.44
Previous studies have speculated that statins may also
exhibit anti-inﬂammatory and antioxidant properties, which
may explain differences in these noncardiovascular out-
comes.42,45,46 Associations of statin treatment before ESRD
transition and its impact on the risk of individual cardiovascular
and noncardiovascular events after transition should be further
examined.
Our study ﬁnding that treatment with a statin before the
transition to ESRD is associated with a lower risk of adverse
outcomes supports the recommendations by the Kidney
Disease: Improving Global Outcomes guidelines3 and the
American College of Cardiology guidelines.4,40 Kidney Dis-
ease: Improving Global Outcomes recommendations for statin
therapy have been mostly based on the results of the SHARP
trial,5 which included men and women aged ≥40 years with a
history of CKD or of receiving dialysis and excluded patients
with a history of MI or coronary revascularization or a deﬁnite
history of chronic liver disease. As opposed to the SHARP
trial, our cohort did include patients with prior MI or liver
disease, and we separately analyzed patients who transitioned
to ESRD. Our study should be noted for its large sample size
and event numbers and for its use of both CMS and VA data
to ascertain medication use, comorbidities, and outcomes.
However, there are several potential limitations to this
study. We adjusted for only known and available confounders
in our analyses; however, residual confounding cannot be
completely eliminated, and a causal relationship cannot be
inferred because of the observational study design. Patients
categorized as not receiving statin therapy may have had
medication compliance or adherence problems, which are
associated with higher mortality risk in this cohort.47 In
addition, we excluded patients without medication data in the
1 year before ESRD transition, which may be a source of
selection bias. Our analysis used a prevalent-user design, and
we were unable to evaluate if patients not receiving statin
therapy discontinued medications because of intolerance or
other adverse effects. Because of a high level of missing lipid
and other laboratory measurements, we were unable to
include these factors in our main multivariable model and we
could not examine other potential confounder laboratory
markers. However, in subgroup analyses among patients with
low-density lipoprotein measurements, we did not observe
effect modiﬁcation in the statin-outcome relationship; and in
sensitivity analysis models that included laboratory variables,
similar results were also observed. Finally, these ﬁndings were
limited by the source population of mostly older male
veterans, thus potentially limiting generalizability to women.
Our study is clinically relevant because it directly supports
the recommendation of treatment with statin therapy in all
patients with NDD-CKD in the pre-ESRD stage and shows that
the beneﬁt of statins is extended after the initiation of dialysis
therapy. Management of pre-ESRD patients by nephrologists
is an essential factor in patient survival after initiation of
dialysis.48–51 Use of renin-angiotensin-aldosterone system
blockade,52 recombinant human erythropoietin,53 predialysis
care by dietitians,54 and a functioning arteriovenous ﬁstula55
have been shown to decrease mortality after the initiation of
dialysis and are recommended. In our study, we additionally
adjusted for factors related to pre-ESRD care, such as
vascular access at initiation and use of nephrology services,
which showed similar associations to those of our main
results. This suggests that our observations were independent
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of these pre-ESRD care markers and further supports the
use of statin therapy in patients with NDD-CKD. Conse-
quently, slightly less than half of our cohort did not receive
adequate statin therapy, according to guideline recommen-
dations. Thus, in concordance with current guidelines that
support treatment with statin therapy in patients with NDD-
CKD, the results of this study support a recommendation of
treatment with statin therapy as it applies to predialysis
management.
In conclusion, our study provides support for guideline
recommendation of statin therapy for all adult patients with
NDD-CKD and speciﬁcally identiﬁes the beneﬁt of statin
therapy in pre-ESRD patients. Further studies are needed to
identify methods for better implementation of the current
guidelines.
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Supplemental Material 
 
Table S1. Subgroup analyses, N and P-interaction by outcome. 
 
  12-month 
  All-Cause Mortality Cardiovascular Mortality Hospitalization Rate 
  N Event/N Group   N Event/N Group   N Event/N Group*   
Subgroup Total  Yes Statin No Statin P-Int Total  Yes Statin No Statin 
P-
Int 
Total*  Yes Statin* No Statin* P-Int 
Age<65 2114/13689 893/6473 1221/7216 
<.0001 
669/12849 6103/318 351/6746 
0.03 
23395/13689 6473/11060 12335/7216 
0.0003 Age65-<75 3068/12799 1643/7331 1425/5468 1038/11665 6732/595 443/4933 21157/12799 7331/12426 8731/5468 
Age≥75 8229/21232 4334/11765 3895/9467 2666/18257 10240/1466 1200/8017 34592/21232 11765/19491 15101/9467 
Non-African 
American 
11362/36738 6010/20501 5352/16237 
0.02 
3720/32667 18382/2096 1624/14285 
0.01 
60526/36738 20501/34397 26129/16237 
0.25 
African 
American 
2044/10976 860/5068 1184/5908 653/10103 4693/283 370/5410 18618/10976 5068/8580 10038/5908 
No Diabetes 4611/16074 1856/6578 2755/9496 
0.02 
1345/14334 5877/579 766/8457 
0.11 
23837/16074 6578/9691 14146/9496 
0.05 
Diabetes 8765/31465 5002/18907 3763/12558 3013/28271 17119/1795 1218/11152 55172/31465 18907/33223 21949/12558 
No CVD 1670/10278 486/3672 1184/6606 
0.002 
385/9600 3460/114 271/6140 
0.05 
12198/10278 3672/3918 8280/6606 
0.002 
CVD 11706/37261 6372/21813 5334/15448 3973/33005 19536/2260 1713/13469 66811/37261 21813/38996 27815/15448 
No Liver 
Disease 
11587/42282 6231/23481 5356/18801 
0.0002 
3860/38037 21241/2177 1683/16796 
0.23 
68355/42282 23481/38812 29543/18801 
0.001 
Liver Disease 1789/5257 627/2004 1162/3253 498/4568 1755/197 301/2813 10654/5257 2004/4102 6552/3253 
Never Smoker 3192/12142 1662/6701 1530/5441 
0.06 
1015/10952 6075/551 464/4877 
0.10 
18381/12142 6701/10363 8018/5441 
0.91 Current Smoker 3623/14025 1861/7381 1762/6644 1170/12632 6681/643 527/5951 25218/14025 7381/13285 11933/6644 
Past Smoker 4228/14198 2422/8407 1806/5791 1426/12713 7569/861 565/5144 23194/14198 8407/13969 9225/5791 
LDL<70 mg/dL 2769/9990 1946/7041 823/2949 
0.82 
914/8949 6324/672 242/2625 
0.62 
17185/9990 7041/12199 4986/2949 
0.64 
LDL≥70 mg/dL 4066/17578 2149/9713 1917/7865 1353/16081 8915/745 608/7166 28761/17578 9713/16050 12711/7865 
No Afib 9896/39592 4989/20920 4907/18672 
0.11 
3114/35860 19047/1665 1449/16813 
0.14 
63467/39592 20920/33826 29641/18672 
0.12 
Afib 3480/7947 1869/4565 1611/3382 1244/6745 3949/709 535/2796 15542/7947 4565/9088 6454/3382 
No ISHD 3941/19635 1426/8189 2515/11446 
0.003 
1041/18079 7620/398 643/10459 
0.07 
27528/19635 8189/10980 16548/11446 
0.001 
ISHD 9435/27904 5432/17296 4003/10608 3317/24526 15376/1976 1341/9150 51481/27904 17296/31934 19547/10608 
No MI 8646/35163 3978/17542 4668/17621 
0.002 
2603/31896 16068/1275 1328/15828 
0.06 
54218/35163 17542/26838 27380/17621 
0.004 
MI 4730/12376 2880/7943 1850/4433 1755/10709 6928/1099 656/3781 24791/12376 7943/16076 8715/4433 
No CHF 4157/21340 1753/10023 2404/11317 
0.0002 
1100/19743 9338/486 614/10405 
0.01 
28978/21340 10023/13227 15751/11317 
0.002 
CHF 9219/26199 5105/15462 4114/10737 3258/22862 13658/1888 1370/9204 50031/26199 15462/29687 20344/10737 
No PVD 6924/29325 3111/14319 3813/15006 
<.0001 
2100/26685 13140/1019 1081/13545 
0.03 
43864/29325 14319/21306 22558/15006 
0.01 
PVD 6452/18214 3747/11166 2705/7048 2258/15920 9856/1355 903/6064 35145/18214 11166/21608 13537/7048 
No 
Cerebrovascular 
8061/32711 3751/16307 4310/16404 
0.001 
2553/29744 14960/1291 1262/14784 
0.33 
50158/32711 16307/25077 25081/16404 
0.02 
Cerebrovascular 5315/14828 3107/9178 2208/5650 1805/12861 8036/1083 722/4825 28851/14828 9178/17837 11014/5650 
No ASCVD 3006/15991 990/6315 2016/9676 
<.0001 
750/14776 5899/256 494/8877 
0.01 
21270/15991 6315/7902 13368/9676 
0.002 
ASCVD 10370/31548 5868/19170 4502/12378 3608/27829 17097/2118 1490/10732 57739/31548 19170/35012 22727/12378 
 
*Hospitalization N Event is the total number of Hospitalizations during the follow-up period. Numerator is larger than the denominator because 
patients may experience multiple hospitalization events 
CVD; Cardiovascular Disease, LDL; low-density lipoprotein, Afib; Atrial Fibrillation, , ISHD; Ischemic Heart Disease; MI; myocardial infarction, 
CHF; congestive heart failure, PVD; peripheral vascular disease, ASCVD; Atherosclerotic Cardiovascular Disease.  
Table S2. Association of pre-ESRD statin therapy (vs. no statin therapy) with post-transition 12-month 
outcomes with additional adjustment for pre-ESRD care indices.  
 
  
12-Month All-Cause 
Mortality 
12-Month Cardiovascular 
Mortality 
12-Month Hospitalization 
Incidence Rate 
Level P HR [95% CI] P HR [95% CI] P IRR [95% CI] 
Adjusted <.0001 0.79[0.76,0.82] <.0001 0.83[0.78,0.88] <.0001 0.89[0.87,0.92] 
Adjusted+Access 
Type <.0001 0.81[0.79,0.84] <.0001 0.85[0.80,0.91] <.0001 0.92[0.89,0.94] 
Adjusted+Any 
VA Nephrology 
Visit <.0001 0.83[0.80,0.86] <.0001 0.86[0.81,0.92] <.0001 0.90[0.88,0.92] 
Adjusted+Any 
CMS 
Nephrology Visit <.0001 0.78[0.76,0.81] <.0001 0.82[0.77,0.87] <.0001 0.90[0.87,0.92] 
Adjusted+Any 
Nephrology Visit <.0001 0.80[0.77,0.82] <.0001 0.83[0.78,0.89] <.0001 0.89[0.87,0.92] 
Adjusted+ # of 
VA Nephrology 
Visits <.0001 0.83[0.80,0.86] <.0001 0.87[0.82,0.92] <.0001 0.91[0.89,0.93] 
Adjusted+ # of 
CMS 
Nephrology 
Visits <.0001 0.79[0.76,0.82] <.0001 0.83[0.78,0.88] <.0001 0.89[0.87,0.92] 
Adjusted+# of 
Any Nephrology 
Visits <.0001 0.79[0.76,0.82] <.0001 0.83[0.78,0.88] <.0001 0.89[0.87,0.92] 
 
 
Adjusted covariates: age, sex, race, and ethnicity, as well as the following comorbidities: CCI, diabetes, 
atherosclerotic CV disease (defined as the presence of MI, PVD or ISHD), atrial fibrillation, CHF and 
cerebrovascular disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S3. Laboratory measurements of 47,720 patients stratified by receipt of statin therapy prior to 
ESRD transition. 
  
N 
missing 
Total 
Statin 
Therapy 
No Statin 
Therapy 
Standardized 
difference 
   47720 25569(53.6) 22151(46.4)   
12-month Averaged Laboratory 
Markers  
          
Albumin (g/dL) 18543 3.5±0.6 3.5±0.6 3.4±0.6 0.09 
Bicarbonate(mEq/L)  17421 23.6±3.9 24.0±3.7 23.0±4.0 0.25 
Blood Urea Nitrogen (mg/dL) 16838 56.9±22.0 57.3±20.7 56.3±23.7 0.05 
Hemoglobin(g/dL) 18393 11.0±1.6 11.0±1.6 10.9±1.7 0.07 
Calcium (mg/dL) 17857 8.8±0.7 8.9±0.6 8.7±0.7 0.19 
Body Mass Index (kg/m2) 13072 29.9±6.5 30.7±6.4 28.9±6.5 0.27 
White Blood Cell Count (x103/μL) 18308 7.7±3.0 7.8±2.8 7.6±3.4 0.07 
 
Standardized differences of ≥0.2 are considered as a meaningful imbalance, where 0.8, 0.5 and 0.2 represent 
large, medium and small imbalances, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S4. Association of pre-ESRD statin therapy (vs. no statin therapy) with post-transition 12-month outcomes, among patients with 
complete laboratory and smoking information. 
 
All-Cause Mortality 
  Unadjusted HR Adjusted HR Adjusted+Lab HR  
 N 
patients 
P HR [95% CI] P HR [95% CI] P HR [95% CI] 
TOTAL 24317 
0.0183 
 
 
0.94[0.89,0.99] 
 
<.0001 0.81[0.77,0.85] <.0001 0.83[0.78,0.87] 
NO 10005 
YES 14312 
 
Cardiovascular Mortality 
  Unadjusted HR Adjusted HR Adjusted+Lab HR 
 N 
patients 
P HR [95% CI] P HR [95% CI] P HR [95% CI] 
TOTAL 22165 
0.2159 1.06[0.97,1.17] <.0001 0.82[0.75,0.90] 0.0002 0.83[0.75,0.91] NO 9095 
YES 13070 
 
Hospitalization  Incidence Rate 
  Unadjusted IRR Adjusted IRR Adjusted + Lab IRR 
 
N 
patients 
P IRR [95% CI] P IRR [95% CI] P IRR [95% CI] 
TOTAL 24317 
0.7646 1.01[0.97,1.04] <.0001 0.89[0.86,0.93] <.0001 0.92[0.88,0.95] NO 10005 
YES 14312 
 
Adjusted covariates: age, sex, race, and ethnicity, as well as the following comorbidities: CCI, diabetes, atherosclerotic CV disease (defined as the 
presence of MI, PVD or ISHD), atrial fibrillation, CHF and cerebrovascular disease. 
Adjusted+Lab covariates: age, sex, race, and ethnicity, as well as the following comorbidities: CCI, diabetes, atherosclerotic CV disease (defined as 
the presence of MI, PVD or ISHD), atrial fibrillation, CHF and cerebrovascular disease, as well as smoking status, last eGFR prior to transition, and 
the following averaged laboratory variables: BMI, hemoglobin, albumin, calcium, white blood cell count, bicarbonate and blood urea nitrogen. 
 
Table S5. Comparison of patients excluded vs. included in laboratory adjusted complete case analyses. 
  Total Excluded 
Included in 
Labs Adjusted 
Model 
Standardized 
difference 
N,(%) 47720 23403 24317  
Cardiovascular Disease(%)     
No 22 19 24 
-0.12 
Yes 78 81 76 
Atrial Fibrillation 17 19 15 -0.11 
ISHD 59 63 54 -0.19 
MI 26 29 23 -0.15 
CHF 55 59 51 -0.16 
PVD 38 42 35 -0.14 
Cerebrovascular Disease 31 34 28 -0.13 
Age (years) 71±11 74±11 69±11 -0.51 
    Age <65 (%) 29 18 39 0.49 
    Age 65-<75 (%) 27 26 27 0.02 
    Age≥75 (%) 44 56 34 -0.46 
Sex (%)     
Female 4 7 2 -0.24 
Race (%)     
White 73 79 67 -0.27 
African American 23 17 29 0.28 
Other 4 4 5 0.02 
Ethnicity (%)     
Hispanic 6 5 7 0.10 
Married (%) 60 66 55 -0.22 
CCI 4[2,6] 4[2,6] 4[2,5] -0.12 
Comorbidities (%)     
Diabetes   66 63 69 0.11 
Anemia 72 72 71 -0.03 
Depression 22 19 26 0.16 
Hyperlipidemia 78 77 79 0.04 
COPD 42 46 39 -0.13 
Peptic Ulcer Disease 7 8 6 -0.07 
Liver Disease   11 10 12 0.04 
Cancer   24 26 23 -0.07 
Smoking Status (%)    
0.19 
Never  30 30 30 
Current  35 30 38 
Past  35 40 32 
eGFR at initiation 
(mL/min/1.73 m2) 
10.1[7.3,13.8] 10.4[7.6,14.4] 9.7[7.1,13.2] -0.13 
12-month Averaged Lipids     
HDL (mg/dL) 40±14 40±13 40±14 0.01 
LDL (mg/dL) 85±35 85±34 86±35 0.02 
Cholesterol (mg/dL) 155±46 154±44 156±46 0.03 
Triglycerides (mg/dL) 124[87,181] 121[85,178] 125[88,182] 0.05 
Initial Dialysis Modality (%)     
Hemodialysis 82 80 84 
0.10 Peritoneal Dialysis 5 5 5 
Other/Unknown 12 14 11 
Initial Access Type (%)        
AV Fistula/AV Graft  21 19 23 
0.10 CVC  70 72 68 
Other 9 9 9 
Pre-ESRD Nephrology Visits        
Any VA or CMS physician 
nephrology visits in the year 
prior to transition (%) 
69 31 77 0.35 
# VA or CMS physician 
nephrology visits in the year 
prior to transition  
3[0,8] 2[0,8] 4[1,8] 0.02 
Any VA nephrology visits in 
the year prior to transition 
(%) 
33 9 57 1.19 
# VA nephrology visits in the 
year prior to transition  
0[0,2] 0[0,0] 1[0,5] 0.83 
Any CMS physician 
nephrology visits in the year 
prior to transition (%) 
43 55 32 -0.49 
# CMS physician nephrology 
visits in the year prior to 
transition  
0[0,5] 1[0,7] 0[0,2] -0.37 
 
eGFR; estimated glomerular filtration rate, CCI; Charlson Comorbidity Index, ISHD; Ischemic Heart Disease; MI; myocardial infarction, CHF; 
congestive heart failure, PVD; peripheral vascular disease, COPD; chronic obstructive pulmonary disease, AV; arteriovenous, CVC; central venous 
catheter, ESRD; end-stage renal disease, VA; Veterans Affairs, CMS; Centers for Medicare and Medicaid Services, LDL; low-density lipoprotein, 
HDL; high-density lipoprotein.   
Data presented as proportion, mean ± standard deviation or median [25th percentile, 75th percentile] where appropriate, and compared between groups 
using standardized differences 
Standardized differences of ≥0.2 are considered as a meaningful imbalance, where 0.8, 0.5 and 0.2 represent large, medium and small imbalances, 
respectively.
Table S6. Baseline characteristics of 38,728 patients matched by pre-ESRD statin therapy. 
  Stain Therapy 
No Statin 
Therapy 
Standardized 
difference 
N,(%) 19364 (50.0) 19364(50.0)  
Cardiovascular Disease(%)    
No 19 23 
0.10 
Yes 81 77 
Atrial Fibrillation 17 17 0.02 
ISHD 60 55 0.12 
MI 28 23 0.12 
CHF 56 53 0.05 
PVD 40 36 0.08 
Cerebrovascular Disease 32 29 0.07 
Age (years) 72±11 71±12 0.06 
    Age <65 (%) 26 30 -0.08 
    Age 65-<75 (%) 28 25 0.06 
    Age≥75 (%) 46 45 0.02 
Sex (%)    
Female 4 4 -0.01 
Race (%)    
White 73 72 0.03 
African American 23 24 -0.03 
Other 4 5 -0.02 
Ethnicity (%)    
Hispanic 6 6 -0.02 
Married (%) 61 60 0.02 
CCI 4[2,6] 4[2,6] 0.05 
Comorbidities (%)    
Diabetes   66 64 0.05 
Anemia 73 71 0.05 
Depression 22 22 0.01 
Hyperlipidemia 90 67 0.58 
COPD 44 42 0.04 
Peptic Ulcer Disease 7 8 -0.03 
Liver Disease   8 14 -0.20 
Cancer   26 25 0.02 
Smoking Status (%)   
0.09 
Never  30 31 
Current  33 36 
Past  37 34 
eGFR at initiation 
(mL/min/1.73 m2) 
10.1[7.4,13.7] 10.0[7.2,13.9] -0.03 
12-month Averaged Lipids    
HDL (mg/dL) 40±13 40±15 -0.03 
LDL (mg/dL) 81±32 94±38 -0.36 
Cholesterol (mg/dL) 150±42 165±50 -0.31 
Triglycerides (mg/dL) 125[89,180] 121[85,182] -0.02 
Initial Dialysis Modality (%)    
Hemodialysis 83 82 
0.03 Peritoneal Dialysis 6 5 
Other/Unknown 12 13 
Initial Access Type (%)    
AV Fistula/AV Graft  23 18 
0.13 CVC  67 72 
Other 9 9 
Pre-ESRD Nephrology Visits    
Any VA or CMS physician 
nephrology visits in the year 
prior to transition (%) 
72 67 0.10 
# VA or CMS physician 
nephrology visits in the year 
prior to transition  
4[0,8] 3[0,7] 0.02 
Any VA nephrology visits in 
the year prior to transition 
(%) 
39 26 0.27 
# VA nephrology visits in the 
year prior to transition  
0[0,3] 0[0,1] 0.26 
Any CMS physician 
nephrology visits in the year 
prior to transition (%) 
41 47 -0.13 
# CMS physician nephrology 
visits in the year prior to 
transition  
0[0,4] 0[0,6] -0.11 
 
eGFR; estimated glomerular filtration rate, CCI; Charlson Comorbidity Index, ISHD; Ischemic Heart Disease; 
MI; myocardial infarction, CHF; congestive heart failure, PVD; peripheral vascular disease, COPD; chronic 
obstructive pulmonary disease, AV; arteriovenous, CVC; central venous catheter, ESRD; end-stage renal 
disease, VA; Veterans Affairs, CMS; Centers for Medicare and Medicaid Services, LDL; low-density 
lipoprotein, HDL; high-density lipoprotein.   
Data presented as proportion, mean ± standard deviation or median [25th percentile, 75th percentile] where 
appropriate, and compared between groups using standardized differences 
Standardized differences of ≥0.2 are considered as a meaningful imbalance, where 0.8, 0.5 and 0.2 represent 
large, medium and small imbalances, respectively. 
 
Table S7. Association of pre-ESRD statin therapy vs. no statin therapy with 12-month all-cause and cardiovascular mortality across 
propensity score analyses 
 
  All-Cause Mortality Cardiovascular Mortality 
Propensity Score Analyses   Unadjusted Adjusted   Unadjusted Adjusted 
  N P HR[95%CI] P HR[95%CI] N P HR[95%CI] P HR[95%CI] 
Matched  38728 <.0001 0.81[0.78,0.85] <.0001 0.79[0.76,0.82] 34627 <.0001 0.86[0.80,0.91] <.0001 0.82[0.77,0.88] 
Adjusted for Propensity Score  47720 <.0001 0.79[0.76,0.81] <.0001 0.79[0.76,0.82] 42771 <.0001 0.82[0.78,0.88] <.0001 0.83[0.78,0.88] 
Tertile 1  15740 <.0001 0.80[0.75,0.86] <.0001 0.71[0.66,0.76] 14113 0.08 0.88[0.77,1.01] <.0001 0.73[0.63,0.84] 
Tertile 2  16239 <.0001 0.77[0.73,0.82] <.0001 0.78[0.74,0.83] 14538 <.0001 0.80[0.73,0.88] <.0001 0.80[0.73,0.88] 
Tertile 3  15741 <.0001 0.82[0.78,0.87] <.0001 0.87[0.82,0.92] 14120 0.004 0.87[0.79,0.96] 0.05 0.91[0.83,1.00] 
 
Adjusted covariates: age, sex, race, and ethnicity, as well as the following comorbidities: CCI, diabetes, atherosclerotic CV disease (defined as the 
presence of MI, PVD or ISHD), atrial fibrillation, CHF and cerebrovascular disease. 
 
 
Table S8. Top Ten Primary Admission Reasons for Hospitalizations in the First Year post-ESRD Transition by pre-ESRD Statin Therapy 
Use. 
 
Primary Hospitalization Reason 
Statin 
Therapy 
No Statin 
Therapy 
Complication of device; implant or graft 1 1 
Septicemia (except in labor) 2 2 
Congestive heart failure; nonhypertensive 3 4 
Hypertension with complications and secondary hypertension 4 3 
Diabetes mellitus with complications 5 8 
Pneumonia (except that caused by tuberculosis or sexually transmitted disease) 6 6 
Chronic kidney disease 7 5 
Coronary atherosclerosis and other heart disease 8 10 
Cardiac dysrhythmias 9 9 
Fluid and electrolyte disorders 10 7 
Figure S1. Cohort Construction. 
 
 
 
 
 85,505 incident ESRD patients 
83,547 incident ESRD patients 
1,958 patients excluded for missing censor 
information 
57,755 incident ESRD patients 
25,792 patients excluded for not having any 
medication information in the 1 year prelude 
10,035 patients excluded for receiving less 
than half a year of continuous Statin 
prescription 
47,720 incident ESRD patients  
22,151 incident ESRD 
patients with no Pre-
ESRD Statin therapy 
25,569 incident ESRD 
patients with Pre-
ESRD Statin therapy 
Figure S2. Associations of pre-ESRD statin therapy vs no statin therapy with 12-month all-cause, cardiovascular mortality, 
and hospitalization incidence rate in individual cardiovascular disease subgroups after adjustment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hazard Ratio for 12-month All-Cause Mortality
10.6 0.8
No AFib
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No ISHD
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No MI
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No CHF
CHF
No PVD
PVD
No Cerebrovascular
Cerebrovascular
No ASCVD
ASCVD
P-Int 
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0.003 
0.002 
<0.001 
<0.001 
0.001 
<0.001 
Hazard Ratio for 12-month Cardiovascular Mortality
10.6 0.8
P-Int 
0.14 
0.07 
0.06 
0.01 
0.03 
0.33 
0.01 
 Incidence Rate Ratio for 12-month Hospitalizations
10.8 0.9
No AFib
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No ISHD
ISHD
No MI
MI
No CHF
CHF
No PVD
PVD
No Cerebrovascular
Cerebrovascular
No ASCVD
ASCVD
P-Int 
0.12 
0.001 
0.004 
0.002 
0.01 
0.02 
0.002 
Figure S3. Associations of pre-ESRD statin therapy vs. no statin therapy comparing 12-
month vs. seven-year follow-up in adjusted models. 
 
 
 
 
 
Adjusted covariates: age, sex, race, and ethnicity, as well as the following comorbidities: CCI, 
diabetes, atherosclerotic CV disease (defined as the presence of MI, PVD or ISHD), atrial 
fibrillation, CHF and cerebrovascular disease. 
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Figure S4. Adjusted restricted cubic splines of the number of pre-ESRD statin therapy days with A) 12-month all-cause 
mortality in 35,604 patients and B) 12-month cardiovascular mortality in 32,076 patients with at least one day of pre-ESRD 
statin therapy (reference: 182 days). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted covariates: age, sex, race, and ethnicity, as well as the following comorbidities: CCI, diabetes, atherosclerotic CV disease 
(defined as the presence of MI, PVD or ISHD), atrial fibrillation, CHF and cerebrovascular disease. 
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